Hikari Dx

Closed portfolio snapshot

According to ClinicalTrials.gov-derived indexes, Hikari Dx sits in the upper quartile of US sponsors by registered trial count (#2,913 of 15,742 sponsors by registered trial count).

4 total trials none currently recruiting 3 completed upper quartile by trial count

Hikari Dx: 4 sponsored US clinical trials, none currently recruiting.

Hikari Dx sponsors 4 registered US clinical trials on ClinicalTrials.gov, none currently recruiting, and 3 completed. The most-studied condition in this pipeline is Antiplatelet Therapy, with 1 trials.

Upper-quartile sponsor footprint

Hikari Dx sits in the upper quartile of the sponsor corpus (#2,913 of 15,742 sponsors by registered trial count) - denser than most sponsors, still short of the top-decile hubs.

Indexed trials (enrollment closed)

4 total, page 1 of 1

ACTIVE NOT RECRUITING

Clinical Validation of the RENISCHEM L-FABP POC Assay

NCT04864847
COMPLETED

T-TAS® wS Method Comparison

NCT06710262
COMPLETED

Clinical Performance Evaluation of T-TAS®01 HD Chip

NCT06087198
COMPLETED

Clinical Performance Evaluation of T-TAS 01 PL Chip

NCT03621020

Therapeutic Areas

Antiplatelet Therapy 1
Contrast Induced Nephropathy 1
Von Willebrand Disease (VWD) 1
Acute Kidney Injury 1
Healthy Donors 1

How the Hikari Dx archive is shaped

4 indexed studies, none listed as recruiting (0% open); 3 completed (75%).

Phase labels are sparse on this sponsor index, so phase mix is not charted here.

Top condition: Antiplatelet Therapy (1 trial), 4 others listed.

How to read a closed sponsor archive

When recruiting_count is zero, the indexed set is completed or otherwise not open. Phase tilt still describes where archived studies sat on the investigational pathway. Re-check ClinicalTrials.gov before acting.

Hikari Dx: archived-pipeline peers nationwide

Peers matched on 4 indexed studies with no current recruiting: volume and archive shape, not condition overlap.

Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot). 2×2 strategic matrix plotting 9 entities by Total trials (X) and Recruiting share (Y), with a crosshair dividing the plot into four quadrants. Higher volume & more openFocused & more openHigher volume, mostly closedSmaller & mostly closed 051015 0%20%40%60%80% Total trials Recruiting share Hikari Dx4D pharma60 Degrees PharmaceuticalsA2 BiotherapeuticsAbdul Latif Jameel Poverty Action Lab10xBio22nd Century Group23andMe3-C Institute for Social Development
Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together. Source: ClinicalTrials.gov (2026-08-08 snapshot).

Hikari Dx sits at or above the median trial volume and at or above the median recruiting share among these 9 nationwide peers -- the two do not always move together.

Sponsors near 4 archived trials

Sponsors with similar archive density (± trial count)

Related

Read our methodology - how this data is sourced, computed, and verified.

What to do with this Hikari Dx page

4 registered trials is a research-attention snapshot, not an endorsement of Hikari Dx or any single study.

  • None of Hikari Dx's trials are currently recruiting in this registry; that can change as new trials post, or check the broader research index. Browse research indexes
  • Antiplatelet Therapy is the condition Hikari Dx studies most, compare against other sponsors active in the same condition before evaluating a specific study. See Antiplatelet Therapy trials
  • Bring the specific trial ID (NCT number) to your own doctor before enrolling, this page is a directory, not medical guidance. Read the trial-finding guide

Trial and recruiting counts reflect ClinicalTrials.gov registry status as of the data vintage above; individual trial eligibility and enrollment status can change.

Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. Hikari Dx pipeline card: 4 registered trials from official public datasets. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.